PLA2R Antibody Testing in Membranous Nephropathy: Diagnostic, Prognostic, and Therapeutic Guidance

Diagnostic Utility

• A positive anti‑PLA2R antibody test in a patient with nephrotic‑range proteinuria and biopsy‑confirmed membranous nephropathy establishes the diagnosis of primary (idiopathic) disease and distinguishes it from secondary causes. 1

• Anti‑PLA2R antibodies are detected in approximately 70–80 % of primary membranous nephropathy cases, indicating an immunologically active, renal‑limited autoimmune disorder. [1][2]

• Patients who are anti‑PLA2R seronegative fall into two groups: (1) those with recent spontaneous remission who may still have primary disease if PLA2R antigen is identified in renal tissue, and (2) those lacking both circulating antibodies and tissue antigen, who are more likely to have secondary membranous nephropathy and should be investigated for lupus, viral hepatitis, malignancy, or drug‑induced disease. [1][2]

• A positive PLA2R test does not exclude secondary etiologies; some individuals with anti‑PLA2R antibodies may concurrently have lupus, hepatitis B/C, or malignancy, requiring clinical judgment to determine whether the association is causal or coincidental. [1][2]

• All patients with membranous nephropathy should be screened for associated conditions (e.g., systemic lupus erythematosus, hepatitis B, medication exposure, malignancy) irrespective of PLA2R antibody status. 3

• For malignancy screening, limit investigations to age‑appropriate cancer tests (colonoscopy, mammography, PSA, chest imaging) unless specific risk factors or symptoms dictate additional studies; the cancer‑MN link is more frequent in older patients and may be causal or coincidental. 1

Prognostic Implications

• Anti‑PLA2R antibody titers measured at diagnosis provide prognostic information that guides treatment decisions. High titers predict lower rates of spontaneous remission, longer duration of proteinuria, and a greater likelihood of requiring immunosuppressive therapy. Low titers are associated with higher probability of spontaneous remission, better response to immunosuppression when needed, and shorter time to remission. 3

• In patients presenting with non‑nephrotic proteinuria, a positive PLA2R test increases the risk of progression to nephrotic‑range proteinuria (hazard ratio ≈ 3.7). These patients warrant closer monitoring and earlier consideration of immunosuppression. 3

• Serial changes in anti‑PLA2R antibody levels precede alterations in proteinuria by ≥ 6 months, offering an early indicator of treatment success or failure. [1][2]

• Immunologic remission (disappearance of anti‑PLA2R antibodies) predicts subsequent clinical remission (reduction in proteinuria); the chance of halving proteinuria rises roughly 6.5‑fold after antibody disappearance. 1

• Rising anti‑PLA2R antibody levels during follow‑up forecast disease relapse before proteinuria increases, allowing pre‑emptive therapeutic adjustments. 1

• Future remission definitions should incorporate both clinical (proteinuria) and immunologic (anti‑PLA2R) parameters, as this combined approach more accurately reflects disease activity than proteinuria alone. [1][2]4

Treatment Initiation Criteria

• Immunosuppressive therapy should be started only in patients meeting high‑risk criteria; PLA2R positivity alone is insufficient.

• Do not treat if all of the following are present: proteinuria < 3.5 g/day, serum albumin > 30 g/L, and estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m². 5

• Consider immunosuppression when any of the following apply:

• Do not use immunosuppression if serum creatinine is persistently ≥ 3.5 mg/dL (eGFR ≤ 30 mL/min/1.73 m²) or if renal ultrasound shows markedly reduced kidney size (< 8 cm). [6][5]4

First‑Line Immunosuppressive Options

• When treatment is indicated, choose among:

Monitoring and Response

• Measure anti‑PLA2R antibody levels every 3 months during therapy.

• Serial antibody monitoring allows early detection of relapse, enabling pre‑emptive adjustments before proteinuria worsens.

Clinical Pitfalls

• Do not assume that PLA2R positivity excludes secondary causes; always evaluate for malignancy, lupus, viral hepatitis, and relevant medications. 1

• Avoid basing treatment decisions on a single antibody measurement; serial trends provide far more reliable guidance.

• Prompt kidney biopsy is essential when eGFR declines rapidly, as this may indicate additional or alternative pathology.

• THSD7A or NELL1 antibodies should not be used alone for diagnosis without biopsy confirmation.

• Weakly positive PLA2R results require confirmation with additional assays or tissue biopsy to rule out false‑positive findings.

PLA2R Antibody Testing in Nephrotic Syndrome

Diagnostic Role of PLA2R Testing

• A positive anti-PLA2R antibody test in a patient with nephrotic syndrome is sufficient to diagnose primary membranous nephropathy (MN) without requiring kidney biopsy, according to the 2023 KDOQI/KDIGO guidelines 7, 8
• The high specificity of anti-PLA2R antibodies (94%) allows high-confidence diagnosis of primary MN while avoiding the risks, costs, and inconvenience of biopsy 7, 8
• Approximately 70-80% of patients with primary MN test positive for anti-PLA2R antibodies 9

When Kidney Biopsy Is Still Necessary

• Despite positive anti-PLA2R antibodies, kidney biopsy remains indicated in situations where suspicion of secondary MN persists, such as lupus, hepatitis B/C, malignancy, or NSAIDs 7, 10
• Kidney biopsy is also necessary in cases of rapidly progressive eGFR decline, patients not responding to treatment, or when assessing disease chronicity to guide treatment intensity decisions 7, 10
• All anti-PLA2R negative patients with nephrotic syndrome require kidney biopsy to establish diagnosis 7

Prognostic and Monitoring Role

• Anti-PLA2R antibody titers provide critical prognostic information beyond diagnosis, with high antibody titers at diagnosis predicting lower rates of spontaneous remission and longer duration of proteinuria 11, 12
• Decreasing antibody titers predict subsequent clinical remission, while increasing levels indicate greater risk of prolonged disease 11, 12

Practical Implementation Algorithm

• The American Journal of Kidney Diseases recommends ordering anti-PLA2R antibody testing in all patients presenting with nephrotic syndrome, and simultaneously evaluating for secondary causes regardless of antibody status 13, 8, 11, 14
• The KDOQI/KDIGO guidelines suggest that high titer (>20 RU/ml) has a 91% positive predictive value for primary MN, and can proceed without biopsy in appropriate clinical context, however this information is not directly cited and intermediate titer (2-20 RU/ml) should be confirmed with immunofluorescence or consider biopsy 7
• Negative (<2 RU/ml) results require kidney biopsy mandatory 7

Critical Pitfalls to Avoid

• Do not assume positive anti-PLA2R antibodies exclude secondary causes—evaluate for malignancy, lupus, hepatitis, and medications regardless of antibody status 11, 14, 9
• Do not use THSD7A or NELL1 antibodies alone without biopsy—these lack the diagnostic accuracy of PLA2R testing 7
• Do not ignore clinical context with weakly positive results—false positives exist and require confirmation 7
• Do not perform single antibody measurements for prognosis—serial measurements showing trajectory are more informative than isolated values 12
• Do not delay biopsy when kidney function is rapidly declining—this suggests alternative or additional pathology requiring histologic evaluation 7, 10

Diagnostic and Management Guidelines for Seronegative Membranous Nephropathy

Diagnostic Evaluation

• In patients with biopsy‑proven membranous nephropathy who test negative for anti‑PLA2R antibodies, immunofluorescence staining of kidney‑biopsy tissue can reveal glomerular PLA2R antigen, confirming primary disease despite seronegative status. 15
• Weakly positive anti‑PLA2R results should be confirmed with repeat testing or alternative assays to rule out false‑negative findings. 15
• Immunofluorescence‑based anti‑PLA2R testing is more sensitive than ELISA and should be employed when ELISA yields negative or borderline results. 15
• When tissue PLA2R staining has not been performed, clinicians should request immunofluorescence staining of the biopsy to clarify disease classification. 15

Tissue Staining Interpretation

• Strong glomerular PLA2R staining on biopsy correlates closely with circulating antibodies and indicates primary membranous nephropathy, even when serum testing is negative due to recent immunologic remission. 15
• Strong tissue PLA2R positivity despite serum negativity indicates recent immunologic remission, conferring an excellent prognosis for primary disease. 15
• Faint or absent PLA2R staining in glomeruli together with negative serology suggests secondary membranous nephropathy or disease driven by alternative antigens. 15
• Absent or faint tissue PLA2R staining mandates thorough evaluation for secondary causes (e.g., malignancy, lupus, hepatitis). 15
• In a cohort of 88 patients, enhanced glomerular PLA2R expression was observed in 61 cases; among the 27 seronegative patients, only faint staining was present and 15 had identifiable secondary causes. 15

Prognostic Indicators

• The extent of chronic interstitial fibrosis and tubular atrophy on biopsy serves as a major adverse prognostic factor, influencing the decision between conservative versus aggressive therapy. 15

Treatment Indications and Contraindications

• Severe nephrotic complications such as acute kidney injury, infections, or thromboembolism justify initiating immunosuppressive therapy. 15
• A ≥30 % rise in serum creatinine over 6–12 months, with eGFR still >25–30 mL/min/1.73 m², is an indication for immunosuppression. 15
• Persistent serum creatinine ≥3.5 mg/dL (eGFR ≤30 mL/min/1.73 m²) or kidney size <8 cm on ultrasound are contraindications to immunosuppressive treatment. 15

First‑Line Immunosuppressive Options (When Indicated)

• Rituximab is the preferred first‑line immunosuppressive agent for seronegative membranous nephropathy when treatment criteria are met, owing to its favorable safety profile. 15
• Cyclophosphamide combined with alternating monthly glucocorticoids for six months is an alternative first‑line regimen. 15

Clinical Pitfalls

• Negative anti‑PLA2R serology does not exclude primary disease; tissue staining can uncover recent remission and should be performed before concluding seronegativity. 15
• Testing for THSD7A or NELL1 antibodies alone is insufficient for diagnosis; PLA2R testing remains the cornerstone, and biopsy confirmation is required when alternative antigens are suspected. 15
• Rapidly declining eGFR warrants prompt kidney biopsy to assess for additional pathology and guide management. 15